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While there have been a number of gene therapy clinical trials using adeno-associated viral (AAV) 
vectors, the majority were safety studies involving local intramuscular delivery; to date only one has 
involved systemic delivery, AAV-SMN for spinal muscular atrophy type 1 (Table 1). Likewise, many of 
the studies in large animals have focussed on local or regional delivery (e.g. Qiao et al. [5] and Le 
Guiner et al. [6]) or have examined the effects of systemic delivery in young puppies (e.g. Yue et 
al.[7]). In this issue of Molecular Therapy, Mack and colleagues [8] employed systemic intravenous 
delivery of an AAV serotype 8 (rAAV8) vector expressing the canine myotubularin (cMTM1) gene in 
the p.N155K canine model of X-linked myotubular myopathy (XLMTM). Skeletal muscle and cardiac 
expression was ensured by a muscle-specific desmin promoter. Importantly, they treated juvenile 
dogs with clinical signs of the disease and showed a clear dose-response to systemic treatment in 
terms of levels of expression of cMTM1 and the functional consequences of such expression. The 
effect of AAV mediated gene therapy was to prolong life substantially with doses of 4 x 1014 vector 
genomes per kilogram (medium dose) or greater (high dose). Other outcome measures included 
global neurological function, spinal reflexes, forelimb extensor and flexor strength, hindlimb 
extensor and flexor strength, gait speed, stride length, peak inspiratory flow and histopathology, all 
of which improved in the medium and high dose groups.  
XLMTM is a consequence of mutations in the MTM1 gene and the associated deficiency of 
myotubularin, a 3-phosphoinositide phosphatase enzyme. Most XLMTM patients develop severe 
muscle weakness leading to respiratory failure and death, typically under 2 years of age. The study 
by Mack and colleagues [4] not only sets a potential dose for human clinical trial but also carefully 
documents the differences in vector biodistribution and expression of myotubularin between 
different skeletal muscles in the canine model. Indeed, the muscle maps of these features are in 
themselves works of art.  
This study follows up a regional delivery trial of the same vector in the same model [5]. The previous 
study had shown remarkable results from a regional infusion of AAV8-cMTM1, leading to a halt in 
the progression of the disease, dramatically improved muscle strength, and a dramatically extended 
survival. That the regional infusion had a body-wide effect was a surprise and the authors speculated 
that the widespread delivery might have been due to an inefficient tourniquet or the presence of 
substantial amounts of the AAV that could enter the circulation after release of the tourniquet. From 
this previous study, it appeared that relatively small levels of myotubularin expression are sufficient 
for rescue of the pathological phenotype, and this was confirmed in the present study. 
Few studies are without flaws. Randomisation lead to a preponderance of females in the control 
groups, while experimental groups were predominately male and this may have affected the 
statistical analysis. However, as the authors note, the study was not sufficiently powered for robust 
statistical analysis, a common problem with breeding mutant dog colonies. Although the authors 
report no difference between affected homozygous females and hemizygous males, there are 
different hormonal profiles between the two sexes that might influence aspects of the manifestation 
of disease. Estrogen has implicated in muscle membrane stability (e.g. [6]) and testosterone has a 
well-known influence on muscle fibre size (e.g. [7]). Such differences might translate into functional 
differences between the treated and control groups. Thus, the reader might wish to focus on the 
comparisons between the different treatment groups, which show a clear dose response for many of 
the outcome measures performed with the dogs. 
Dog models have proven invaluable in the development of gene therapies for haemophilia [8] and 
are likely to prove so for XLMTM, Duchenne muscular dystrophy (DMD), and other neuromuscular 
disorders. Quite recently, body-wide but patchy expression of a highly engineered microdystrophin 
was demonstrated in a dog model of Duchenne muscular dystrophy (DMD) treated with intravenous 
AAV as juveniles [9]. Importantly the DMD dog study also did not report any safety concerns. Of 
course, it is important to recognise where there are differences between animal models and the 
human condition. Although the dog model of XLMTM shows many features of the human condition, 
it develops respiratory problems in the later stages of the disease whereas infants with XLMTM 
present with respiratory failure at birth. Consequently, the dramatic amelioration of the disease 
seen in the murine and canine models of XLMTM may not precisely replicated by a similar 
improvement in man. 
The current study lays the foundation for a human clinical trial of systemic AAV-MTN in myotubular 
myopathy. In parallel, there are a number of groups that propose to undertake human clinical trials 
of systemic AAV microdystrophin delivery for the treatment of DMD, although none are registered 
to date on https://clinicaltrials.gov/. Enthusiasm for such trials follows the presentation at the 
October 2016 Annual Congress of the World Muscle Society given by Jerry Mendell for the results of 
the AAV-SMN1 treatment of SMA type 1[10]. The presentation reported a good safety profile and an 
improved clinical outcome, especially in those infants treated at the earliest ages.  
All of the above information points towards a likely rapid increase in the number of clinical trials 
using systemic delivery of AAV-mediated gene therapies, and the next few years could see a 
resurgence of interest and potentially promising results for gene therapy of neuromuscular 
disorders. 
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Table 1 
Clinicaltrials.gov 
identifier 
 
Trial Route Associated 
publications 
NCT00428935 
   
Safety Study of Mini-dystrophin Gene to 
Treat Duchenne Muscular Dystrophy 
 
Intramuscular [1] 
NCT00494195 
 
Gene Transfer Therapy for Treating 
Children and Adults With Limb Girdle 
Muscular Dystrophy Type 2D (LGMD2D) 
 
Intramuscular [2] 
NCT01344798 
 
Clinical Study of AAV1-gamma-
sarcoglycan Gene Therapy for Limb 
Girdle Muscular Dystrophy Type 2C 
 
Intramuscular none 
NCT01519349 
 
Follistatin Gene Transfer to Patients 
With Becker Muscular Dystrophy and 
Sporadic Inclusion Body Myositis 
 
Intramuscular [3, 4] 
NCT02122952 
 
Gene Transfer Clinical Trial for Spinal 
Muscular Atrophy Type 1 
 
Systemic (IV) ongoing 
NCT02354781 
 
Clinical Intramuscular Gene Transfer of 
rAAV1.CMV.huFollistatin344 Trial to 
Patients With Duchenne Muscular 
Dystrophy 
 
Intramuscular ongoing 
A summary of human clinical trials of AAV based gene transfer in neuromuscular diseases. 
